Company Encyclopedia
View More
name
Celularity
CELU.US
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn’s disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn’s) and degenerative disease; and PDA-002 for treating facioscapulohumeral muscular dystrophy.
1.912 T
CELU.USMarket value -Rank by Market Cap -/-

Financial Score

21/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking298/400
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE5731.84%A
    • Profit Margin-198.75%E
    • Gross Margin26.12%C
  • Growth ScoreE
    • Revenue YoY-15.81%E
    • Net Profit YoY-130.08%E
    • Total Assets YoY-11.33%E
    • Net Assets YoY-216.28%E
  • Cash ScoreD
    • Cash Flow Margin-50.32%D
    • OCF YoY-15.81%E
  • Operating ScoreD
    • Turnover0.33D
  • Debt ScoreE
    • Gearing Ratio117.59%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Celularity Inc. held annual stockholder meeting

    Celularity Inc. held its Annual Meeting of Stockholders on December 19, 2025. Peter Diamandis, Diane Parks, and Geoffrey Ling were elected to the Board of Directors. EisnerAmper LLP was ratified as the independent public accounting firm for 2025. An amendment to increase shares under the 2021 Equity Incentive Plan was not approved.

    Reuters·
    US
    CELU
    +16.00%
    Reuters·
    US
    CELU
    +16.00%

    Celularity Inc. secures financing with Philip Barach for regenerative medicine, with senior secured term loan & secured convertible note.

    Today, in Florham Park, New Jersey, Celularity Inc. (Nasdaq: CELU) revealed that it has secured two significant funding agreements. The agreements include a senior secured term loan and a secured convertible note financing with Philip A. Barach, who is the co-founder and ex-president of DoubleLine Capital LP. Celularity focuses on regenerative and cellular medicine for age-related and degenerative diseases. The agreements are subject to the finalization of formal transaction agreements, which is anticipated to occur soon.

    Unusual Whales·
    US
    CELU
    +16.00%
    Unusual Whales·
    US
    CELU
    +16.00%

    Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision | CELU Stock News

    Celularity Inc. announced binding term sheets for financing transactions, securing up to $12 million to support its strategic priorities in longevity and human performance. The financing includes a $7 million senior secured term loan and $5 million in secured convertible notes, with additional funding contingent on certain conditions. The transactions, involving Philip A. Barach, are private placements exempt from registration requirements. This funding aims to advance Celularity's placental-derived technologies and align its organizational structure with its strategic goals.

    StockTitan·
    US
    CELU
    +16.00%
    StockTitan·
    US
    CELU
    +16.00%

    Celularity (NASDAQ:CELU) Trading 0.4% Higher - Should You Buy?

    Celularity (NASDAQ:CELU) shares rose 0.4% to $1.98, with a trading volume down 20% from average. Analysts have mixed ratings: WBB Securities upgraded to 'buy' with a $6 target, while Weiss Ratings maintained a 'sell' rating. The stock's consensus rating is 'Hold'. Celularity reported better-than-expected quarterly earnings, with a negative return on equity. Hedge funds have been active in trading the stock. Celularity develops cell therapies for cancer and other diseases.

    Market Beat·
    US
    CELU
    +16.00%
    Market Beat·
    US
    CELU
    +16.00%

    Celularity Inc Receives FDA Warning Letter

    On December 1, 2025, Celularity Inc received a warning letter from the FDA regarding marketing materials for Interfyl. Key Highlights: FDA letter addresses marketing claims for Interfyl.No impact on manufacturing or shipping of products.Company committed to resolving FDA concerns.No expected material impact on financial expectations.Original SEC Filing: Celularity Inc [ CELU ] - 8-K - Dec. 05, 2025DisclaimerThis is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

    TradingView·
    US
    CELU
    +16.00%
    TradingView·
    US
    CELU
    +16.00%
    © 2025 Longbridge｜Disclaimer